SRX Global Makes Strategic Investment in ARMR Sciences
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 23 2026
0mins
Source: Newsfilter
- Strategic Investment: SRX Global has announced a strategic investment in ARMR Sciences, a clinical-stage biodefense company focused on developing medical countermeasures against synthetic drugs like fentanyl, showcasing the company's forward-looking approach in the biopharmaceutical sector.
- Product Advancement: ARMR's lead product, ARMR-100, has successfully generated an anti-fentanyl immune response in clinical trials and demonstrated favorable safety data, marking a significant milestone in its efforts to protect humans from fentanyl's effects.
- Clinical Trial Phase: Currently in Phase 1/2 clinical trials, ARMR-100 aims to produce antibodies capable of binding to lethal synthetic drugs, with the expectation that it can provide protection for 6-12 months in healthy adults, indicating strong market potential.
- Future Collaboration: ARMR Sciences CEO Collin Gage expressed gratitude for SRX Global's investment and belief in their vision, suggesting that their partnership could drive further development of this potentially life-saving solution.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SRXH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SRXH
About SRXH
SRx Global Inc. is an artificial intelligence (AI)-driven platform focused on investments in high-conviction operating companies, strategic assets, and technology-enabled opportunities. The Company leverages proprietary technology, data analytics, and disciplined capital allocation to identify and manage investments across multiple sectors. Its portfolio includes EMJX and Halo pets. EMJX is a digital-asset treasury platform designed as a treasury operating system, applying models, artificial intelligence, and systematic risk controls to multi-asset digital treasury management. Halo pets is engaged in selling premium pet products for dogs and cats. Halo pets offer Dry Food, Freeze-Dried Raw, Wet Food, Toppers, Dental, Treats & Chews, and others. Its dry food includes Freeze-Dried Raw Beef Meal Bites 14 oz, Freeze-Dried Raw Turkey Meal Bites 14 oz, Holistic Vegan Plant-Based with Superfoods Recipe Adult Dry Dog Food, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
SRX Global Makes Strategic Investment in Greenland Mines Ltd.
- Strategic Investment: SRX Global has announced a strategic investment in Greenland Mines Ltd., aiming to enhance long-term shareholder value through investments in high-conviction operating companies and assets, indicating the company's focus on critical mineral resources.
- Multi-Asset Platform: Greenland Mines is focused on developing strategic assets such as rare earth magnet materials and precious metals, building a multi-asset platform that aims to link Greenland resources with downstream industrial infrastructure, advancing the vision of a North Atlantic Critical Metals Corridor.
- Technology-Driven: SRX Global leverages proprietary technology and data analytics, implementing disciplined capital allocation strategies to identify and manage investment opportunities across multiple sectors, showcasing its advantages in technology-driven investment.
- Market Outlook: This investment not only strengthens SRX's positioning in the critical minerals sector but also has the potential to enhance its competitiveness and influence in the global market through resource and technology integration.
See More
SRx Global Shares Plunge After EMJ Crypto Acquisition Announcement
- Stock Price Plunge: SRx Global (SRXH) shares fell nearly 20% on Wednesday, hitting a four-month low as investor enthusiasm for the company's acquisition of EMJ Crypto Technologies and AI expansion quickly faded, reflecting market concerns over compliance with shareholder equity requirements.
- Compliance Pressure: The company announced a stock consolidation effective July 6, 2026, combining every 60 shares into one, yet did not disclose the expected number of outstanding shares post-consolidation, facing pressure to meet NYSE American's minimum stockholders' equity requirements.
- Strategic Transformation: Following the acquisition of EMJX, SRx Global rebranded itself, shifting from a pet wellness company to an AI-driven digital asset platform, marking a significant transition that is expected to enhance its competitive position in the market.
- Increased Investment Activity: The company has invested in multiple firms over the past two months, including Astro Capital and Uber Technologies, indicating its intent to expand in the digital asset space, although its stock performance has been poor, it remains actively positioning for future growth.
See More
SRX Global Approves 60-to-1 Reverse Stock Split
- Reverse Stock Split: SRX Global's board has approved a 60-to-1 reverse stock split aimed at increasing the share price to attract more investors, although this move may raise concerns about the company's financial health.
- Effective Date: The consolidation will take effect on July 6, 2026, and is expected to impact the stock's liquidity, potentially leading to fluctuations in trading volume shortly after the effective date.
- Market Reaction Anticipation: Reverse splits are often viewed as a signal of financial distress, which could lead to a decline in investor confidence and negatively affect the stock price, especially in the immediate aftermath of the split.
- Strategic Adjustment: By implementing this reverse stock split, SRX Global may be taking necessary strategic steps to improve its market image and attract institutional investors, although this could also be a direct response to its current poor stock performance.
See More
SRX Global Makes Strategic Investment in ARMR Sciences
- Strategic Investment: SRX Global has announced a strategic investment in ARMR Sciences, a clinical-stage biodefense company focused on developing medical countermeasures against synthetic drugs like fentanyl, showcasing the company's forward-looking approach in the biopharmaceutical sector.
- Product Advancement: ARMR's lead product, ARMR-100, has successfully generated an anti-fentanyl immune response in clinical trials and demonstrated favorable safety data, marking a significant milestone in its efforts to protect humans from fentanyl's effects.
- Clinical Trial Phase: Currently in Phase 1/2 clinical trials, ARMR-100 aims to produce antibodies capable of binding to lethal synthetic drugs, with the expectation that it can provide protection for 6-12 months in healthy adults, indicating strong market potential.
- Future Collaboration: ARMR Sciences CEO Collin Gage expressed gratitude for SRX Global's investment and belief in their vision, suggesting that their partnership could drive further development of this potentially life-saving solution.
See More
SRX Global Completes EMJX Acquisition and Rebranding
- Company Rebranding: Following the acquisition of EMJ Crypto Technologies, Inc., SRx Health Solutions, Inc. has officially rebranded as SRX Global Inc., continuing to trade on NYSE American under the ticker SRXH, reflecting a strategic shift towards digital assets.
- Acquisition Impact: This acquisition enables SRX Global to leverage EMJX's AI-driven platform, focusing on capital allocation into high-conviction operating companies and assets, thereby enhancing shareholder returns and competitive positioning in the market.
- Management Team Integration: The newly merged company's management team includes Kent Cunningham as CEO, Eric Jackson as President and Head of Asset Management, and Nina Martinez as CFO, ensuring deep expertise in both digital and traditional asset markets.
- Investment Strategy: SRX Global has already invested in high-potential companies such as Astro Capital, Opendoor Technologies, Uber Technologies, and Optimi Health Corp., demonstrating an active approach to capital allocation and growth drivers aimed at maximizing shareholder value.
See More
SRx Health Solutions and EMJ Crypto Enter Definitive Merger Agreement
- Merger Agreement: SRx Health Solutions has entered into a definitive merger agreement with EMJ Crypto Technologies, marking a strategic consolidation in the digital asset space that is expected to enhance their market competitiveness.
- Equity Acquisition: The company has acquired a 4.99% stake in Smartkem, Inc. through a shelf take down, which not only strengthens its investment portfolio in advanced materials but also lays the groundwork for potential future technological collaborations.
- Convertible Preferred Securities Purchase: SRx Health has also purchased convertible preferred securities through a non-brokered private placement, which will provide flexibility in its capital structure and may play a crucial role in future financing efforts.
- Registration Statement Filed: The company has filed a Registration Statement on Form S-4 with the SEC, planning to send an Information Statement and Prospectus to shareholders post-transaction, ensuring transparency and compliance with regulatory requirements.
See More
SRX Global Makes Strategic Investment in Greenland Mines Ltd.
- Strategic Investment: SRX Global has announced a strategic investment in Greenland Mines Ltd., aiming to enhance long-term shareholder value through investments in high-conviction operating companies and assets, indicating the company's focus on critical mineral resources.
- Multi-Asset Platform: Greenland Mines is focused on developing strategic assets such as rare earth magnet materials and precious metals, building a multi-asset platform that aims to link Greenland resources with downstream industrial infrastructure, advancing the vision of a North Atlantic Critical Metals Corridor.
- Technology-Driven: SRX Global leverages proprietary technology and data analytics, implementing disciplined capital allocation strategies to identify and manage investment opportunities across multiple sectors, showcasing its advantages in technology-driven investment.
- Market Outlook: This investment not only strengthens SRX's positioning in the critical minerals sector but also has the potential to enhance its competitiveness and influence in the global market through resource and technology integration.
See More
SRx Global Shares Plunge After EMJ Crypto Acquisition Announcement
- Stock Price Plunge: SRx Global (SRXH) shares fell nearly 20% on Wednesday, hitting a four-month low as investor enthusiasm for the company's acquisition of EMJ Crypto Technologies and AI expansion quickly faded, reflecting market concerns over compliance with shareholder equity requirements.
- Compliance Pressure: The company announced a stock consolidation effective July 6, 2026, combining every 60 shares into one, yet did not disclose the expected number of outstanding shares post-consolidation, facing pressure to meet NYSE American's minimum stockholders' equity requirements.
- Strategic Transformation: Following the acquisition of EMJX, SRx Global rebranded itself, shifting from a pet wellness company to an AI-driven digital asset platform, marking a significant transition that is expected to enhance its competitive position in the market.
- Increased Investment Activity: The company has invested in multiple firms over the past two months, including Astro Capital and Uber Technologies, indicating its intent to expand in the digital asset space, although its stock performance has been poor, it remains actively positioning for future growth.
See More
SRX Global Approves 60-to-1 Reverse Stock Split
- Reverse Stock Split: SRX Global's board has approved a 60-to-1 reverse stock split aimed at increasing the share price to attract more investors, although this move may raise concerns about the company's financial health.
- Effective Date: The consolidation will take effect on July 6, 2026, and is expected to impact the stock's liquidity, potentially leading to fluctuations in trading volume shortly after the effective date.
- Market Reaction Anticipation: Reverse splits are often viewed as a signal of financial distress, which could lead to a decline in investor confidence and negatively affect the stock price, especially in the immediate aftermath of the split.
- Strategic Adjustment: By implementing this reverse stock split, SRX Global may be taking necessary strategic steps to improve its market image and attract institutional investors, although this could also be a direct response to its current poor stock performance.
See More
SRX Global Makes Strategic Investment in ARMR Sciences
- Strategic Investment: SRX Global has announced a strategic investment in ARMR Sciences, a clinical-stage biodefense company focused on developing medical countermeasures against synthetic drugs like fentanyl, showcasing the company's forward-looking approach in the biopharmaceutical sector.
- Product Advancement: ARMR's lead product, ARMR-100, has successfully generated an anti-fentanyl immune response in clinical trials and demonstrated favorable safety data, marking a significant milestone in its efforts to protect humans from fentanyl's effects.
- Clinical Trial Phase: Currently in Phase 1/2 clinical trials, ARMR-100 aims to produce antibodies capable of binding to lethal synthetic drugs, with the expectation that it can provide protection for 6-12 months in healthy adults, indicating strong market potential.
- Future Collaboration: ARMR Sciences CEO Collin Gage expressed gratitude for SRX Global's investment and belief in their vision, suggesting that their partnership could drive further development of this potentially life-saving solution.
See More
SRX Global Completes EMJX Acquisition and Rebranding
- Company Rebranding: Following the acquisition of EMJ Crypto Technologies, Inc., SRx Health Solutions, Inc. has officially rebranded as SRX Global Inc., continuing to trade on NYSE American under the ticker SRXH, reflecting a strategic shift towards digital assets.
- Acquisition Impact: This acquisition enables SRX Global to leverage EMJX's AI-driven platform, focusing on capital allocation into high-conviction operating companies and assets, thereby enhancing shareholder returns and competitive positioning in the market.
- Management Team Integration: The newly merged company's management team includes Kent Cunningham as CEO, Eric Jackson as President and Head of Asset Management, and Nina Martinez as CFO, ensuring deep expertise in both digital and traditional asset markets.
- Investment Strategy: SRX Global has already invested in high-potential companies such as Astro Capital, Opendoor Technologies, Uber Technologies, and Optimi Health Corp., demonstrating an active approach to capital allocation and growth drivers aimed at maximizing shareholder value.
See More
SRx Health Solutions and EMJ Crypto Enter Definitive Merger Agreement
- Merger Agreement: SRx Health Solutions has entered into a definitive merger agreement with EMJ Crypto Technologies, marking a strategic consolidation in the digital asset space that is expected to enhance their market competitiveness.
- Equity Acquisition: The company has acquired a 4.99% stake in Smartkem, Inc. through a shelf take down, which not only strengthens its investment portfolio in advanced materials but also lays the groundwork for potential future technological collaborations.
- Convertible Preferred Securities Purchase: SRx Health has also purchased convertible preferred securities through a non-brokered private placement, which will provide flexibility in its capital structure and may play a crucial role in future financing efforts.
- Registration Statement Filed: The company has filed a Registration Statement on Form S-4 with the SEC, planning to send an Information Statement and Prospectus to shareholders post-transaction, ensuring transparency and compliance with regulatory requirements.
See More
